Literature DB >> 11107442

The phosphoprotein Op18/stathmin is differentially expressed in ovarian cancer.

D K Price1, J R Ball, Z Bahrani-Mostafavi, J C Vachris, J S Kaufman, R W Naumann, R V Higgins, J B Hall.   

Abstract

To identify potential prognostic indicators of ovarian cancer and identify targets for therapeutic strategies, mRNA differential display was used to analyze gene expression differences in normal, benign, and cancerous ovarian tissue. One cDNA isolated by this technique, Op18/stathmin, is a highly conserved gene that is reported to have many different functions within a cell, including signal transduction, control of the cell cycle, and the regulation of microtubules. Quantitative Northern blot analysis of 12 malignant ovarian samples, 8 benign ovarian tumors, and 10 normal ovarian tissue samples demonstrated overexpression of Op18/stathmin mRNA in the malignant cancers. Immunohistochemistry showed an apparent overexpression of Op18/stathmin protein level and an association with proliferating cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11107442     DOI: 10.3109/07357900009012204

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  22 in total

Review 1.  Molecular genetics of ovarian cancer.

Authors:  A N Shelling; W Foulkes
Journal:  Mol Biotechnol       Date:  2001-09       Impact factor: 2.695

2.  The microtubule cytoskeleton is required for a G2 cell cycle delay in cancer cells lacking stathmin and p53.

Authors:  Bruce K Carney; Victoria Caruso Silva; Lynne Cassimeris
Journal:  Cytoskeleton (Hoboken)       Date:  2012-03-29

3.  Characterization and detection of cellular and proteomic alterations in stable stathmin-overexpressing, taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE difference gel electrophoresis.

Authors:  Manimalha Balasubramani; Chitose Nakao; Guy T Uechi; John Cardamone; Kathy Kamath; Kristen L Leslie; Raghavan Balachandran; Leslie Wilson; Billy W Day; Mary Ann Jordan
Journal:  Mutat Res       Date:  2010-09-09       Impact factor: 2.433

4.  Anti-centrosome antibodies in breast cancer are the expression of autoimmunity.

Authors:  Marie-Claire Maroun; Ofelia Olivero; Leonard Lipovich; Azadeh Stark; Larry Tait; Sudeshna Bandyopadhyay; Matthew Burke; Richard Zarbo; Dhananjay Chitale; S David Nathanson; Mike Long; Carol Peebles; Félix Fernández Madrid
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

5.  Epstein-Barr virus-encoded LMP1 triggers regulation of the ERK-mediated Op18/stathmin signaling pathway in association with cell cycle.

Authors:  Xuechi Lin; Min Tang; Yongguang Tao; Lili Li; Sufang Liu; Lili Guo; Zijian Li; Xiaoqian Ma; Juan Xu; Ya Cao
Journal:  Cancer Sci       Date:  2012-04-30       Impact factor: 6.716

6.  Inhibiting proliferation and enhancing chemosensitivity to taxanes in osteosarcoma cells by RNA interference-mediated downregulation of stathmin expression.

Authors:  Rui Wang; Ke Dong; Fang Lin; Xi Wang; Ping Gao; San-Hua Wei; Shi-Yin Cheng; Hui-Zhong Zhang
Journal:  Mol Med       Date:  2007 Nov-Dec       Impact factor: 6.354

7.  Identification of candidate lung cancer susceptibility genes in mouse using oligonucleotide arrays.

Authors:  W J Lemon; H Bernert; H Sun; Y Wang; M You
Journal:  J Med Genet       Date:  2002-09       Impact factor: 6.318

8.  Stathmin/Op18 is a novel mediator of vinblastine activity.

Authors:  Francois Devred; Philipp O Tsvetkov; Pascale Barbier; Diane Allegro; Susan Band Horwitz; Alexander A Makarov; Vincent Peyrot
Journal:  FEBS Lett       Date:  2008-06-25       Impact factor: 4.124

9.  Expression of stathmin/op18 as a significant prognostic factor for cervical carcinoma patients.

Authors:  Wang Xi; Wang Rui; Lin Fang; Dong Ke; Gao Ping; Zhang Hui-Zhong
Journal:  J Cancer Res Clin Oncol       Date:  2008-11-26       Impact factor: 4.553

Review 10.  c-Jun N-Terminal Kinases Mediate a Wide Range of Targets in the Metastatic Cascade.

Authors:  Nancy D Ebelt; Michael A Cantrell; Carla L Van Den Berg
Journal:  Genes Cancer       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.